A randomized, double-blind, placebo-controlled, parallel-group study of the safety, tolerability, and pharmacokinetic properties of TPN102 tablets in healthy Chinese individuals after a single oral dose.
Latest Information Update: 20 Jan 2026
At a glance
- Drugs TPN 102 (Primary)
- Indications Seizures
- Focus Adverse reactions
Most Recent Events
- 20 Jan 2026 New trial record